Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
672 Views
eMediNexus 02 June 2021
Eli Lilly and Company India has been granted permission for emergency use of its antibody drugs combination for the treatment of mild to moderate COVID-19 in India.
Permission has been given for restricted emergency use of the monoclonal antibody drugs, bamlanivimab 700 mg and etesevimab 1400 mg, given together in patients with mild to moderate COVID-19, stated the company. The combination of bamlanivimab and etesevimab has been given Emergency Use Authorization in the US and some EU countries as well, for the treatment of the viral disease.
In May, the company was granted permission for the emergency use of baricitinib along with remdesivir, to treat suspected or laboratory confirmed COVID-19 in the country… (ET Healthworld – PTI, June 2, 2021)
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}